Catalyst for Change. Viral Hepatitis Control Program Country Model Ukraine. Zahedul Islam
|
|
- Grace Arnold
- 5 years ago
- Views:
Transcription
1 Catalyst for Change Viral Hepatitis Control Program Country Model Ukraine Zahedul Islam Director: Treatment, Procurement & Supply Alliance for Public Health Ukraine
2 Alliance for Public Health Alliance for Public Health is an international non-governmental professional organization working in the area of HIV/AIDS, tuberculosis, viral hepatitis and other harmful diseases in Ukraine and the EECA region. APH operates in partnership with the government and civil society organizations to deliver its programs APH is also partners with 30 Linking Organizations of International HIV/AIDS Alliance, UK worldwide
3 Epidemiological Background (HPV) Population: as of August 1st, 2018 Estimated 3% HCV prevalence in Ukraine ( ) More than registered cases of HCV-infection in % were detected with Viral Hepatitis C Markers among new HIV cases persons were co-infected with HIV/HVC as of January 1st, % HIV prevalence among estimated number of PWID HCV prevalence among PWID in Ukraine exceeds overall average, reaching 63.9% ( , Alliance bio-behavioral research) persons living with HIV
4 Alliance Key Interventions in Viral Hepatitis Awareness and Advocacy Prevention Diagnostics, treatment and care Capacity building
5 Testing, Diagnostics and HCV Treatment in the Penitentiary Sector of Ukraine December July 2018 In 2017 in close cooperation with the Ministry of Justice Alliance was the first to launch HCV testing, diagnostics and treatment with DAAs in the Penitentiary sector of Ukraine HIV+ patients tested for HCV 139 HIV+ prisoners were laboratory diagnosed for HCV 50 HIV+ persons received HCV treatment 74% HCV+ results 84% HCV confirmed % treatment success attained
6 Scaling up Accessible and Effective HCV Treatment through Community-Based Treatment Model for Key Populations in Resource Constrained Ukraine Key populations: PWID, OST patients, SW, MSM, PWID partners, war veterans Enrollment criteria: Fibrosis F2 (priority F3, F4), METAVIR Project key objectives: Implementation of community-supported DAAs-based HCV treatment model for key populations Access to laboratory diagnostics (treatment monitoring and follow-up) Operational research Effectiveness of HCV Treatment Program for MARPs
7 Model: community-supported HCV treatment END of TREATMEN T Step 1. Sharing information on the Project via NGOs, communities and medical staff; referrals to HCV diagnostic Step 8. Treatment success evaluation (SVR12) Step 2. Case-manager informs potential patients about enrollment criteria and refers patients to a doctor Step 3. A doctor advices a list of examinations required to take enrollment decision MDT Diagnostics Step 7. Laboratory monitoring of treatment Step 6. Social support provided by a case manager; 3 sessions on reinfection prevention Step 5. Doctor selects the treatment regimen for enrolled patients Step 4.Multi-disciplinary team consisting of a doctor, a nurse and a social worker takes joint decision on patients enrollment (MDT)
8 Multidisciplinary Approach to Patient Oriented Integrated Services Multidisciplinary team (MDT) takes joint decision on patients enrollment Doctor & Nurse Consultations Diagnostics Administering treatment Dispensing medicines Clinical monitoring Laboratory monitoring Re-directing to TB and HIV services Hello, I am your case manager Case manager Counseling Scheduling visits to doctors Three sessions on reinfection prevention Linking ART and OST
9 Patient-Oriented Activities: Re-infection Prevention Education (3 sessions)
10 Treatment Outcomes DAAs-based courses of HCV-infection treatment were provided, 1421 out of them interferon-free sof/riba and led/sof courses 1873 patients successfully finished full course of treatment 98,2% retention on treatment 34 patients (1,8%) terminated treatment on different reasons, 6 out of them re-started treatment within the Project 1837 patients were diagnosed (PCR RNA HCV) after 12 weeks of treatment (SVR 12) 95% treatment success
11 Treatment Outcomes as per Key Group (n=1837) SVR12 8% 4% 4% 1% 98% 97% 96% 96% 98% 96% 81% 95% 95% 94% 94% 93% PWID 92% PWID partners SW MSM PWID&PWHL Advocates
12 PWID Treatment Success (n=1479) SVR 12 94,6% 96,8% 97,4% 92,3% 93,2% 91,7% 781/ /208 90/93 227/233 55/59 55/60 HCV/HIV HCV PWID in remission Active PWID PWID on OST
13 Treatment Success (SVR 12) as per HIV Status (n=1837) % ,8% 95,3% 80% % % HIV + HIV % 0% Tested for SVR 12 Reached SWR 12 Treatment success %
14 Challenges Lack of awareness and knowledge about HCV treatment High diagnostic cost was a barrier for enrollment (Alliance provided 50% discount) Limited knowledge of medical staff on DAA administration and treatment No access to medicines to treat adverse reactions during treatment
15 Conclusion Significant reduction of HepC treatment cost Alliance agreed price (900 USD/12w treatment course) for Sof and Sof/led became a benchmark for the state procurement DAAs-based regimens were integrated in National HCV treatment guidelines and in the essential medicine list PWID identified as KP in National HCV treatment guidelines Model is recognized as the best practice in the national HCV elimination strategy
16 Thank you!
Epidemiological Background (Ukraine)
Scaling up Accessible and Effective HCV Treatment through Community-based Treatment Model for Most Vulnerable Populations in the Resource Constrained Ukraine Anton Basenko Country Focal Point: PITCH Alliance
More informationHepatitis and HIV Co-Infection: Situation in Ukraine.
2nd Central and Eastern European Meeting on Viral Hepatitis and Co-Infection with HIV Hepatitis and HIV Co-Infection: Situation in Ukraine. Pavlo Skala Associate Director: Policy & Partnership Ukraine
More informationCivil Society Driven Response in Ukraine: A program making a difference and bringing results
Civil Society Driven Response in Ukraine: A program making a difference and bringing results CATIE Forum Making it work: From Planning to Practice October 16th, 2015 Andriy Klepikov International HIV/AIDS
More informationRolling up HCV treatment programs for PWIDs in Ukraine
Rolling up HCV treatment programs for PWIDs in Ukraine www.aph.or g.ua Ludmila Maistat Alliance for Public Health VHPB Meeting, Highlight undeserved groups for screening, prevention and treatment of viral
More informationRegional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model
Regional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model Background for the program development Problem areas Access to the whole HIV-care
More informationCollaboration among TB/HIV CSOs and HIV and TB programs in Ukraine
Wolfheze 2013 16 th Wolfheze Workshop 28-31 May 2013, The Hague, The Netherlands Collaboration among TB/HIV CSOs and HIV and TB programs in Ukraine Zahedul Islam International HIV/AIDS Alliance in Ukraine
More informationTetiana Kyrychenko MD. Poltava Regional HIV/AIDS Prevention and Control Center. 4TH CEE MEETING ON VIRAL HEPATITIS AND HIV October 2018, Prague
Tetiana Kyrychenko MD Poltava Regional HIV/AIDS Prevention and Control Center 4TH CEE MEETING ON VIRAL HEPATITIS AND HIV 11-12 October 2018, Prague tanakyrychenko@gmail.com Disclosures No relevant conflicts
More informationHepatitis C Elimination Program Georgia
Hepatitis C Elimination Program Georgia Maia Butsashvili, MD, MS, PhD Health Research Union (HRU)/Clinic NEOLAB National HCV Committee International School of Public Health High prevalence of HCV in Georgia
More informationIntegration of collaborative TB/HIV activities with harm reduction services
Integration of collaborative TB/HIV activities with harm reduction services Maryna Zelenskaya Ph D State service on HIV/AIDS and other socially diseases control, Head of Department on HIV/AIDS combating
More informationAccess to HCV treatment in Eastern Europe and Central Asia. Natalia Kravchenko (Alliance for Public Health) Liudmyla Maistat (Medicines Patent Pool)
Access to HCV treatment in Eastern Europe and Central Asia Natalia Kravchenko (Alliance for Public Health) Liudmyla Maistat (Medicines Patent Pool) Disclosure Presenter: Natalia Kravchenko FINANCIAL DISCLOSURE:
More informationDifferentiated Care for Antiretroviral Therapy for Key Populations: Case Examples from the LINKAGES Project
Differentiated Care for Antiretroviral Therapy for Key Populations: Case Examples from the LINKAGES Project NOVEMBER 2017 An estimated 37 million people are living with HIV today. A response to the need
More informationThe Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC
The Comprehensive Package: The simple truth about our response to drug related HIV Dr. Monica Beg, Signe Rotberga UNODC HIV among injecting drug users Why is it so important? 30% global HIV infections
More informationHarm Reduction in Nigeria
Harm Reduction in Nigeria Needs, gaps, and responses to ensure access to effective HIV prevention, treatment and care for people who inject drugs February 2018 This document is made possible by the generous
More informationTB: INTEGRATION IN HARM REDUCTION PACKAGES. ICF "AIDS Foundation East-West (AFEW Ukraine) Tbilisi, 2015
TB: INTEGRATION IN HARM REDUCTION PACKAGES ICF "AIDS Foundation East-West (AFEW Ukraine) Tbilisi, 2015 Ʃ = 185 760 «D» 45 083 / 38 126 TB Epidemiology in Ukraine Active TB prevalence in Ukraine (per 100,
More informationThe National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015
The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015 December 21, 2015 2 December 21, 2015 3 Can we eliminate hepatitis C? Treatments December 21, 2015 4 We Have the Roadmap
More informationCOUNTRY TABLE. MONTENEGRO.
EPIDEMIOLOGICAL DATA Indicator Data Source of data/additional notes re data Year of estimate Population 620 029 National Census data 2011 Estimated number of people who inject drugs (PWID) 1282 (95%CI
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationSTI and HIV Prevention and Care among Sex Workers
Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS STI and HIV Prevention and Care among Sex Workers Annette Verster and Michelle Rodolph
More informationepidemic among vulnerable groups
Project TUBIDU Empowering public health system and civil society to fight tuberculosis epidemic among vulnerable groups Prepared by: Aljona Kurbatova, NIHD Maarja Sukles, NIHD Liga Rusmane, LTBF What is
More informationACCESS AND IMPLEMENTATION OF IFN-FREE THERAPY IN PEOPLE WHO INJECT DRUGS : WHERE TO FROM HERE FOR LOW AND MIDDLE INCOME COUNTRIES
ACCESS AND IMPLEMENTATION OF IFN-FREE THERAPY IN PEOPLE WHO INJECT DRUGS : WHERE TO FROM HERE FOR LOW AND MIDDLE INCOME COUNTRIES Niklas Luhmann Médecins du Monde 09 October 2015 International Symposium
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationHIV and Hepatitis Prevention Programmes in Eastern Europe Case Example: Georgia
HIV and Hepatitis Prevention Programmes in Eastern Europe Case Example: Georgia Nikoloz Chkhartishvili, MD, MS, PhD Deputy Executive Director for Research Infectious Diseases, AIDS and Clinical Immunology
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationHepatitis C treatment for people who inject drugs: are directacting antivirals cost-effective?
Hepatitis C treatment for people who inject drugs: are directacting antivirals cost-effective? Daniëla K. van Santen, Anneke S. de Vos, Amy Matser, Sophie B. Willemse, Karen Lindenburg, Mirjam E.E. Kretzschmar,
More informationNational Hepatitis C Elimination Program of Georgia
European Roundtable on Hepatitis Cure & Eradication 2015 9-10 September 2015, Frankfurt, Germany National Hepatitis C Elimination Program of Georgia Tengiz Tsertsvadze MD, PhD Director General Infectious
More informationAdapting Treatment 2.0 in Viet Nam - Toward Universal and Sustainable Access -
Adapting Treatment 2.0 in Viet Nam - Toward Universal and Sustainable Access - Associate Professor, Bui Duc Duong, MD, Ph.D. Deputy Director General, Ministry of Health Socialist Republic of Viet Nam HIV
More informationPCORI s Hepatitis C Workshop. Arlington, VA October 17, 2014
PCORI s Hepatitis C Workshop Arlington, VA October 17, 2014 1 Plenary Session: Review and Discussion of Prioritized CER Questions Eric B. Bass, MD Director, Johns Hopkins Evidence-based Practice Center
More informationDirect Clinical Services
Health4Men Health4Men Established in 2008 as a project of the Anova Health Institute, in partnership with the South African Department of Health, and in response to the NSP. The brief was to develop MSMfocused
More informationTANZANIA NATIONAL STRATEGIC PLAN FOR CONTROL OF VIRAL HEPATITIS
TANZANIA NATIONAL STRATEGIC PLAN FOR CONTROL OF VIRAL HEPATITIS 2017-2021 A Draft ANGELINA C. SIJAONA THE UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERLY AND CHILDREN
More informationComparison of HCV Recurrent Viremia Rates in All-Oral and Interferon-Based Regimens
Comparison of HCV Recurrent Viremia Rates in All-Oral and Interferon-Based Regimens Presented by: Tyler Raycraft Doctor of Medicine Candidate, 2019 University of British Columbia Clinical Researcher Vancouver
More informationHIV and HCV coinfection - Barriers in Central and Eastern Europe
HIV and HCV coinfection - Barriers in Central and Eastern Europe Jerzy Jaroszewicz Vice President of Polish Association for the Study of Liver Department of Infectious Diseases and Hepatology, Medical
More informationTajikistan National Report. Summary HARM REDUCTION WORKS FUND IT! Arguments for strategic investment. Summary of National Report: Tajikistan
HARM REDUCTION WORKS FUND IT! National Report Summary Arguments for strategic investment With the support of The present document contains a summary of the key conclusions and recommendations provided
More informationSituation Report. on the Status of HIV/TB/HCV Prevention and Treatment and OST Programs in Donetsk and Luhansk oblasts (as of 23 January 2017)
вул. 5 Dilova Ділова, st., building 5, корпус 10A, 10-А, 9th floor 9-й 03150 поверх, Kyiv, Ukraine 03150, м. Київ Тел.: Tel.: (+380 044 490 44) 490-5485 Факс: Fax: (+380 044 490 44) 490-5489 info@aph.org.ua
More informationPREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS
PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS Holly Hagan, PhD Professor Co-Director, Center for Drug Use and HIV Research Principal Investigator, HCV Synthesis Project New York University HCV prevalence
More informationNATIONAL PROGRAMME ON THE RESPONSE TO THE HIV EPIDEMIC
NATIONAL PROGRAMME ON THE RESPONSE TO THE HIV EPIDEMIC 2013-2016 TABLE OF CONTENTS Abbreviations... 3 I Terms and definitions... 4 II Introduction... 6 III Goal of the National Programme on the Response
More informationCOUNTRY REPORT: EPIDEMIOLOGICAL SITUATIONS AND PROJECT ACTIVITIES
COUNTRY REPORT: EPIDEMIOLOGICAL SITUATIONS AND PROJECT ACTIVITIES BIRUTE SEMENAITE, MEDICAL DIVISION OF PRISON DEPARTMENT AT THE MINISTRY OF JUSTICE OF THE REPUBLIC OF LITHUANIA LITHUANIAN PRISONS. BACKGROUND:
More informationToronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally A call for coordinated action Disclaimer Toronto declaration is not aiming to reinvent the wheel or interfere
More informationBruce Kreter, PharmD Senior Director, Global HCV Medical Affairs Gilead Sciences, Inc.
CDC Foundation & Viral Hepatitis Action Coalition: Summit for the Elimination of Hepatitis B and Hepatitis C as Public Health Threats in the United States Bruce Kreter, PharmD Senior Director, Global HCV
More informationMarket Access in Hepatitis C Learnings From HIV
Market Access in Hepatitis C Learnings From HIV Allan F. Miranda Ph.D., MBA. Therapeutic Lead Immunology and Virology- Government Affairs and Market Access Our CREDO Throughout our global organization
More informationGLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy
GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA The critical need to scale up opioid substitution therapy Craig McClure IAS Executive Director Outline of Presentation 1.
More informationInternational HIV/AIDS Alliance in Ukraine at the International AIDS Conference, Melbourne, July 2014
International HIV/AIDS Alliance in Ukraine at the International AIDS Conference, Melbourne, July 2014 In 2014 and beyond the International HIV/AIDS Alliance in Ukraine continues to strengthen the responses
More informationEuropean HIV-Hepatitis Testing Week
European HIV-Hepatitis Testing Week COBATEST Network meeting Barcelona, Spain 14 May 2018 Lauren Combs, CHIP, Rigshospitalet, University of Copenhagen Background The first Testing Week was launched by
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationIntegrated harm reduction services for drug users and homeless people. Katrin Schiffer
Integrated harm reduction services for drug users and homeless people Katrin Schiffer Content Introduction Presentation of Correlation Network Harm Reduction in a nutshell basic principles and critical
More informationCountry progress report - Bangladesh. Global AIDS Monitoring 2017
Country progress report - Bangladesh Global AIDS Monitoring 2017 2 Contents Overall - Fast-track targets Commitment 1 - Ensure that 30 million people living with HIV have access to treatment through meeting
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item March Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item 12.3 28 March 2014 Hepatitis Improving the health of patients with viral hepatitis Report by the Secretariat 1. The Executive Board at
More informationHIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons
HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons Ministerial Meeting on Urgent response to the HIV/AIDS epidemics in the Commonwealth of Independent States Moscow, 31 March
More informationMay 26-28, 2010, Almaty, Kazakhstan November 2011
Progress note of the recommendations of the 16 th TB/HIV Core Group Meeting Report May 26-28, 2010, Almaty, Kazakhstan November 2011 1. Structural and organizational barriers The Core Group urges Ministries
More informationTreating Patient, Not Disease: People-Centered Approach. 7th TB Symposium Ministry of Health of the Kyrgyz Republic and Médecins Sans Frontières
Treating Patient, Not Disease: People-Centered Approach 1-2 March, 2018, BISHKEK, KYRGYZSTAN Hepatitis C screening and treatment among DR-TB patients in Armenia Ohanna Kirakosyan Medical Activity Manager
More informationGLOBAL AIDS MONITORING REPORT
KINGDOM OF SAUDI ARABIA MINISTRY OF HEALTH GLOBAL AIDS MONITORING REPORT COUNTRY PROGRESS REPORT 2017 KINGDOM OF SAUDI ARABIA Submission date: March 29, 2018 1 Overview The Global AIDS Monitoring 2017
More informationThe role of UNODC in working law enforcement agencies to promote harm reduction. IHRC, Bangkok, 23 April 2009
The role of UNODC in working law enforcement agencies to promote harm reduction IHRC, Bangkok, 23 April 2009 Drug control has focused mostly on law enforcement Public health which is the first principle
More informationSTRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL ( ) POLICY BRIEF
PROGRAMME NATIONAL DE LUTTE CONTRE LES HEPATITES STRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL (2019-2023) POLICY BRIEF 1 INVESTING IN THE FIGHT AGAINST HEPATITIS B AND C IN SENEGAL NATIONAL STRATEGIC
More informationHEPATITIS C: CANADIAN CONTEXT
1 OPTIMAL ADHERENCE DURING HCV TREATMENT AMONGST ACTIVE DRUG USERS IN A COMMUNITY-BASED PROGRAM IN TORONTO, CANADA KATE MASON RESEARCHER SEPTEMBER 8, 2016 HEPATITIS C: CANADIAN CONTEXT 250,000 Canadians
More informationPEPFAR SOLUTIONS PLATFORM (BETA) WHAT WAS THE PROBLEM? WHAT IS THE SOLUTION?
Creating Equitable and Sustainable Access for HIV Products and Services in Vietnam Using a Total Market Approach to Reach Epidemic Control among Key Populations COUNTRY: Vietnam IMPLEMENTING PARTNER: PATH
More informationWhy are the targets a game-changer? What is the Fast-Track Cities Initiative and its connection to ?
Frequently Asked Questions about 90-90-90 Targets, the HIV Care Continuum, the Updated National HIV AIDS Strategy (NHAS), and the Fast-Track Cities Initiative What is the origin of the 90-90-90 targets?
More informationHepatitis C The NHS Model. Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL
Hepatitis C The NHS Model Professor Graham R Foster Professor of Hepatology Barts Liver Centre QMUL The NHS Approach Background The strategy Tactics The NHS Approach Background The strategy Tactics NHSE
More informationDISCLOSURE ESPACE GAIA, FIRST DCR IN PARIS SINCE OCTOBER /06/2017
ESPACE GAIA, FIRST DCR IN PARIS SINCE OCTOBER 2016 First results and perspectives DISCLOSURE DR Elisabeth AVRIL Presentation : Espace GAIA, first DCR in Paris : first results and perspectives Mundipharma,
More informationProtecting and Promoting Health and Equity
Meeting People Where They re at: Locating SFDPH s Hepatitis C Initiative in a Legacy of Drug User Health Services Protecting and Promoting Health and Equity Presented by: Katie Burk, MPH 1 San Francisco
More informationBUDGET AND RESOURCE ALLOCATION MATRIX
Strategic Direction/Function ILO Strengthened capacity of young people, youth-led organizations, key service providers and partners to develop, implement, monitor and evaluate HIV prevention programmes
More informationRECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS
RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS The International Network on Hepatitis in Substance users (INHSU) Olav Dalgard Oslo Grebely J et al Int J
More information26 28 May 2010, Almaty, Kazkhstan. Nina Kerimi UNODC Regional Project Coordinator 1
The 16 th Core Group Meeting of the TB/HIV Working Group 26 28 May 2010, Almaty, Kazkhstan Nina Kerimi UNODC Regional Project Coordinator 1 UNODC Regional Office for Central Asia covers 6 countries: AZE,
More informationWHO Strategy and Goals for Viral Hepatitis Elimination
WHO Strategy and Goals for Viral Hepatitis Elimination No Disclosures Outline 1. Global strategy for elimination WHO targets and rationale 2. The global response so far Gaps in achieving the HBV and HCV
More informationGlobal health sector strategies on HIV, viral hepatitis and sexually transmitted infections ( )
Regional Committee for Europe 65th session EUR/RC65/Inf.Doc./3 Vilnius, Lithuania, 14 17 September 2015 2 September 2015 150680 Provisional agenda item 3 ORIGINAL: ENGLISH Global health sector strategies
More informationAnnouncement for a Principal Recipient for HIV and TB program Funded by the Global Fund to Fight AIDS, TB and Malaria for
Announcement for a Principal Recipient for HIV and TB program Funded by the Global Fund to Fight AIDS, TB and Malaria for 2018-2020 ************************************************************ Thailand
More informationHIV, HBV and HCV testing policy experiences and lessons learned.
HIV, HBV and HCV testing policy experiences and lessons learned. Contents HIV and viral hepatitis: distinct epidemics at different stages of evolution Epidemiology: transmission, prevalence, incidence
More informationVHPB MEETING ANTWERP 2014 ACHIEVEMENTS AND CHALLENGES IN PREVENTION AND CONTROL OF VIRAL HEPATITIS
POST-IT @ VHPB MEETING ANTWERP 2014 ACHIEVEMENTS AND CHALLENGES IN PREVENTION AND CONTROL OF VIRAL HEPATITIS East challenges Risk group vaccination problems Problems of anti-vaccine lobby Importance of
More informationSection 7: Providing HCV testing and treatment to people who inject drugs
Section 7: Providing HCV testing and treatment to people who inject drugs Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective
More informationUNGASS COUNTRY PROGRESS REPORT SINGAPORE
UNGASS COUNTRY PROGRESS REPORT SINGAPORE Submission date: 14 March 2008 Reporting period: January 2006 December 2007 I. Overview of the HIV/AIDS epidemic Singapore is categorized as a low-prevalence epidemic.
More informationKey issues for HIV testing and
Key issues for HIV testing and counselling in Europe Martin C Donoghoe Programme Manager HIV/AIDS, STI &Viral Hepatitis Programme WHO Europe Key issues for HIV testing & counselling in Europe HIV epidemics
More informationDr. Mark R. Dybul Executive Director of the Global Fund to Fight AIDS Tuberculosis and Malaria
Dr. Mark R. Dybul of the Global Fund to Fight AIDS Tuberculosis and Malaria Dear Dr. Dybul, With this letter we, the undersigned organizations representing civil society including organizations representing
More information(differs from NICE who recommend 24 weeks for all) *Child Pugh A only
Treatment Recommendations for the management of patients with Chronic HCV Infection February 2016 These are recommendations for treatment based on a consensus meeting of experienced treating physicians
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationThe new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany
The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach Ines Perea Ministry of Health, Germany Reasons for a new strategy in 2016 New international agreements (SDG s) Renewed political
More informationHIV/AIDS IN EASTERN EUROPE AND CENTRAL ASIA (EECA) Charles Ssonko HIV/TB/Hepatitis Adviser Medecins Sans Frontieres
HIV/AIDS IN EASTERN EUROPE AND CENTRAL ASIA (EECA) Charles Ssonko HIV/TB/Hepatitis Adviser Medecins Sans Frontieres Objectives The Epidemiology of HIV/AIDS in the EECA Region (Trends) o The Burden of HIV/AIDS
More informationAnnex A: Impact, Outcome and Coverage Indicators (including Glossary of Terms)
IMPACT INDICATORS (INDICATORS PER GOAL) HIV/AIDS TUBERCULOSIS MALARIA Reduced HIV prevalence among sexually active population Reduced HIV prevalence in specific groups (sex workers, clients of sex workers,
More informationIPT IMPLEMENTATION- SWAZILAND EXPERIENCE
IPT IMPLEMENTATION- SWAZILAND EXPERIENCE Gugu Mchunu-National TB/HIV coordinator Programmatic Management of Latent TB infection consultation meeting Seoul, Republic of Korea,27-28 APRIL,2016 TB Epidemiology
More informationContextual overview with reference to MDG Goal 6 and projection for Post-2015
Contextual overview with reference to MDG Goal 6 and projection for Post-2015 10th Partnership Annual Conference Side Event Combating HIV and TB through a joint regional action Helsinki, Finland November
More informationMODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative
More informationImproving NSP and Harm Reduction Services. Jason Farrell, European HCV and Drug Use Initiative
Improving NSP and Harm Reduction Services Jason Farrell, European HCV and Drug Use Initiative Presentation Overview With the growing need to treat HCV, NSP programs have been identified in numerous stakeholder
More informationTechnical Guidance Note for Global Fund HIV Proposals
Technical Guidance Note for Global Fund HIV Proposals UNAIDS I World Health Organization I 2011 Rationale for including this activity in the proposal The World Health Organization (WHO), the Joint United
More informationKENYA AIDS STRATEGIC FRAMEWORK 2014/ /2019
KENYA AIDS STRATEGIC FRAMEWORK 2014/2015-2018/2019 2 Kenya Aids Strategic Framework 2014/2015 2018/2019 1. Introduction The Kenya AIDS Strategic Framework (KASF 2014/15 2018/19) has been developed in the
More informationRapid Assessment of Sexual and Reproductive Health
NIGER Rapid Assessment of Sexual and Reproductive Health and HIV Linkages This summary highlights the experiences, results and actions from the implementation of the Rapid Assessment Tool for Sexual and
More informationGovernment of Malawi. SUMMARY of the National Plan of Action to Combat Gender-Based Violence in Malawi
Government of Malawi SUMMARY of the National Plan of Action to Combat Gender-Based Violence in Malawi 2014 2020 Ministry of Gender, Children, Disability and Social Welfare Private Bag 330, Lilongwe 3 JULY
More informationUpdate in hepatitis C virus infection
Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward
More informationGlobal, regional and national strategic planning for viral hepatitis prevention and control
Global, regional and national strategic planning for viral hepatitis prevention and control Dr Antons Mozalevskis WHO Regional Office for Europe VHPB Baltic Meeting 19 20 November 2015 Riga, Latvia Presentation
More informationHighlight underserved groups for screening, prevention and treatment of viral hepatitis B and C in Europe LJUBLJANA, SLOVENIA March 2016
Viral Hepatitis Prevention Board Highlight underserved groups for screening, prevention and treatment of viral hepatitis B and C in Europe LJUBLJANA, SLOVENIA 10-11 March 2016 Objectives To define and
More informationThe Ontario Hepatitis C Multidisciplinary Team Model. Samantha Earl, RN, Senior Policy Analyst 2013 CATIE Forum Wednesday September 18, 2013
The Ontario Hepatitis C Multidisciplinary Team Model Samantha Earl, RN, Senior Policy Analyst 2013 CATIE Forum Wednesday September 18, 2013 History The Ontario Hepatitis Nursing Program was announced by
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationThe EACS Standard of Care initiative. The Standard of Care for HIV and Coinfections in Europe meeting in Rome: a reminder
The EACS Standard of Care initiative. The Standard of Care for HIV and Coinfections in Europe meeting in Rome: a reminder Antonella d Arminio Monforte, University of Milan Cristina Mussini, University
More informationL aderenza del trattamento e strategie
L aderenza del trattamento e strategie di prevenzione per la reinfezione HIV/HCV coinfetto alla terapia Teresa Bini UO Malattie Infettive ASST Santi Paolo e Carlo Università di Milano PWID A preliminary
More informationHIV Quality Improvement Initiatives in Mozambique
HIV Quality Improvement Initiatives in Mozambique HEALTHQUAL INTERNATIONAL: ACLN 2012 Kampala, Uganda Dr. Mussa Calu, MD Joseph Lara, MPH Dr. Isabel Pereira, MD MPH KEY HIV/AIDS INDICATORS 1. HIV Prevalence
More informationThe birthof the Dutch National hepatitis plan
Improving Mental Health by Sharing Knowledge The birthof the Dutch National hepatitis plan A success story in many parts Esther Croes MD PhD WHO: framework for global action In 2012 the WHO stated: viral
More informationHIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS
POLICY BRIEF HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS CONSOLIDATED GUIDELINES JULY 2014 Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for
More informationOverlapping Epidemics:HIV/TB/IDU. Time for action! Sergey Filippovych, Associate Director: Treatment Olga Denisiuk Programme Officer : HIV/TB
Overlapping Epidemics:HIV/TB/IDU. Time for action! Sergey Filippovych, Associate Director: Treatment Olga Denisiuk Programme Officer : HIV/TB 1 www.aidsalliance.org.ua Ukraine Ukraine: key context information:
More informationACHAP LESSONS LEARNED IN BOTSWANA KEY INITIATIVES
ACHAP Together with our company s foundation, a U.S.-based, private foundation, and the Bill & Melinda Gates Foundation, we established the African Comprehensive HIV/AIDS Partnerships (ACHAP) in 2000 to
More informationUnited Nations Office on Drugs and Crime (UNODC)
UNAIDS 2016 REPORT United Nations Office on Drugs and Crime (UNODC) Unified Budget Results and Accountability Framework (UBRAF) 2016-2021 2 Contents Achievements 2 Introduction 2 HIV services for key populations
More informationPrevention and control of hepatitis B and C in the European Region of WHO
Prevention and control of hepatitis B and C in the European Region of WHO Viral Hepatitis Prevention Board Dr Nedret Emiroglu WHO Regional Office for Europe Burden of viral hepatitis in the European Region
More informationNASTAD AT-A-GLANCE. Britten Pund, Director, Health Care Access
NASTAD AT-A-GLANCE Britten Pund, Director, Health Care Access ABOUT NASTAD 2 WHO, WHAT, AND HOW Who is NASTAD? Leading non-partisan non-profit association representing public health officials who administer
More informationVol. 5, No. 18 Spring 2010
Vol. 5, No. 18 Spring 2010 IN THIS ISSUE: Snapshot Knowledge Hub activities to date, in numbers Knowledge Hub Calendar Find out about training workshops and other upcoming events Knowledge Hub in Review
More informationAction Plan on HIV/AIDS in the EU and neighbouring countries:
Action Plan on HIV/AIDS in the EU and neighbouring countries: 2014-2016 Matthias Schuppe Policy Officer Health Threats Unit DG Health and Consumers European Commission Outline o EU policy framework on
More information